Inflammatory Bowel Disease

US Food and Drug Administration

First subcutaneous formulation of infliximab submitted to FDA

4 January 2023

Celltrion USA has submitted a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act for CT-P13 SC for the treatment of inflammatory bowel disease (IBD).  The submission is based on results from the Phase III pivotal data that evaluated the efficacy and safety of CT-P13 SC as maintenance therapy […]

The start-up changing the game for IBD 

16 November 2021

Jenny Bailey, CEO of Ferryx tells Lu Rahman how its leading product FX856 came to life and how it’s a game-changer for inflammatory bowel disease since it can act during active inflammation.  Ferryx is an innovative bio-tech start-up. It is a University of Bristol spin-out with a focus on gut health and IBD in particular. Its mission is to […]

Funding for new microbiome marker to aid treatment of IBD

15 June 2021

Genetic Analysis (GA) has announced that the Norwegian Research Council has approved its grant application of NOK 16 million (€1.6 million) for its project developing new innovative microbiome-based diagnostics to be used to aid selection and treatment of Inflammatory Bowel Disease (IBD) patients. In this project, GA will develop an easy to use, in vitro […]